We scan new podcasts and send you the top 5 insights daily.
Bostwick says AI can help molecule design and preclinical packages, but claiming discovery is the main bottleneck misses the cost center. He notes 90% of costs and failures sit in clinical development, so he wants companies using AI to compress biomedical timelines and trials, not just generate many compounds.
The $5 billion cost to develop a drug is primarily driven by the high failure rate (9 out of 10) in late-stage trials. AI's biggest financial impact will be predicting which drugs will succeed, drastically reducing wasted R&D. This efficiency is what will ultimately make drugs more affordable.
The transformational power of AI in life sciences isn't just designing novel molecules, which fails to solve the costly clinical development bottleneck. Instead, agentic AI provides immense leverage to individual scientists, automating tasks like protocol writing and experiment analysis that previously took weeks.
While AI can accelerate the ideation phase of drug discovery, the primary bottleneck remains the slow, expensive, and human-dependent clinical trial process. We are already "drowning in good ideas," so generating more with AI doesn't solve the fundamental constraint of testing them.
The process of testing drugs in humans—clinical development—is a massive, under-studied bottleneck, accounting for 70% of drug development costs. Despite its importance, there is surprisingly little public knowledge, academic research, or even basic documentation on how to improve this crucial stage.
The highest-value application of AI in clinical development is in the design phase. By simulating trial outcomes with historical data and virtual patient cohorts, companies can identify and resolve potential bottlenecks, like flawed protocols or recruitment issues, before committing massive resources. This
If AI compresses discovery from ten years down to four, the rest of the healthcare ecosystem will bottleneck. Organizations must pre-emptively reform clinical trials with agencies like ARPA-H and overhaul manufacturing capacity to absorb higher drug throughput.
While AI for novel drug discovery has lofty goals, its most practical value lies in accelerating development. This includes applying AI to de-risked assets for new indications, improving delivery methods, and designing faster, more effective clinical trials, which is where the real bottleneck lies.
While AI is on the verge of cracking preclinical challenges, the biggest problem is the high drug failure rate in human trials. The next wave of innovation will use AI to design molecules for properties that predict human efficacy, addressing the fundamental reason drugs fail late-stage.
Early clinical trials offer the highest return on AI investment because they involve fewer patients, lower costs, and shorter timelines. Applying models here enables developers to enrich patient selection and forecast late-phase outcomes before committing massive capital to phase three studies.
Despite major scientific advances, the key metrics of drug R&D—a ~13-year timeline, 90-95% clinical failure rate, and billion-dollar costs—have remained unchanged for two decades. This profound lack of productivity improvement creates the urgent need for a systematic, AI-driven overhaul.